9th Oct 2007 11:27
Celsis International PLC09 October 2007 CELSIS INTERNATIONAL PLC NOTIFICATION OF RESULTS 9 October 2007: Celsis International plc, the life sciences products andlaboratory services company, will announce its interim results for the sixmonths ended 30 September 2007 on Wednesday 31 October 2007. There will be a presentation to analysts on the day at 9.30am, held at FinancialDynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB. For moreinformation please contact Gemma Cross Brown on +44 (0)207 269 7125. Enquiries: Celsis International plc Tel: 01223 598 428Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Lara MottBen Atwell Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life scienceproducts and laboratory services to the pharmaceutical, biopharmaceutical, andconsumer products industries through its three business areas; rapid detection,analytical and drug development services and ADME-Tox in vitro technologies.The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliversubstantial time and cost savings to its customers, in addition to ensuringproduct quality and safety for consumers. Using proprietary technology, theCelsis Rapid Detection division provides diagnostic systems for the rapiddetection of contamination. These systems provide significant economic value byreducing the time it takes to test and release raw materials, in process andfinished goods to market. Celsis Analytical Services division provides costeffective outsourced laboratory testing services to pharmaceutical andbiopharmaceutical companies. Its comprehensive service offerings include a fullspectrum of laboratory services from drug development and discovery toanalytical chemistry and biological sciences to stability storage and testing.Celsis In Vitro Technologies (Celsis IVT) supplies in vitro testing products tothe pharmaceutical and biotechnology industries. IVT's in vitro products screendrug compounds early in the discovery process, thereby reducing the time andcost of drug development. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Celadon Pharmaceuticals